Your browser doesn't support javascript.
loading
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Saliby, Renée Maria; Labaki, Chris; Jammihal, Tejas R; Xie, Wanling; Sun, Maxine; Shah, Valisha; Saad, Eddy; Kane, M Harry; Kashima, Soki; Sadak, Katherine; El Zarif, Talal; Poduval, Deepak; Motzer, Robert J; Powles, Thomas; Rini, Brian I; Albiges, Laurence; Pal, Sumanta K; McGregor, Bradley A; McKay, Rana R; Signoretti, Sabina; Van Allen, Eliezer M; Shukla, Sachet A; Choueiri, Toni K; Braun, David A.
Afiliação
  • Saliby RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center of Molecular and Cellular Oncology (CMCO), Yale University, New Haven, CT, USA.
  • Labaki C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Jammihal TR; Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Xie W; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sun M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Shah V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Saad E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Kane MH; Center of Molecular and Cellular Oncology (CMCO), Yale University, New Haven, CT, USA.
  • Kashima S; Center of Molecular and Cellular Oncology (CMCO), Yale University, New Haven, CT, USA; Department of Urology, Akita University School of Medicine, Akita, Japan.
  • Sadak K; Center of Molecular and Cellular Oncology (CMCO), Yale University, New Haven, CT, USA.
  • El Zarif T; Yale School of Medicine, New Haven, CT, USA.
  • Poduval D; Center of Molecular and Cellular Oncology (CMCO), Yale University, New Haven, CT, USA.
  • Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical Center, New York, NY, USA.
  • Powles T; Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, UK.
  • Rini BI; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Albiges L; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
  • Pal SK; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • McGregor BA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • McKay RR; Moores Cancer Center, University of California San Diego Health, La Jolla, CA, USA.
  • Signoretti S; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
  • Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Shukla SA; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.
  • Braun DA; Center of Molecular and Cellular Oncology (CMCO), Yale University, New Haven, CT, USA. Electronic address: david.braun@yale.edu.
Cancer Cell ; 42(5): 732-735, 2024 May 13.
Article em En | MEDLINE | ID: mdl-38579722
ABSTRACT
Saliby et al. show that a machine learning approach can accurately classify clear cell renal cell carcinoma (RCC) into distinct molecular subtypes using transcriptomic data. When applied to tumors biospecimens from the JAVELIN Renal 101 (JR101) trial, a benefit is observed with immune checkpoint inhibitor (ICI)-based therapy across all molecular subtypes.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Inibidores de Checkpoint Imunológico / Imunoterapia / Neoplasias Renais Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Inibidores de Checkpoint Imunológico / Imunoterapia / Neoplasias Renais Idioma: En Ano de publicação: 2024 Tipo de documento: Article